Publicacions (43) Publicacions de Gonzalo Lopez Montoya

2024

  1. Women’s neuroplasticity during gestation, childbirth and postpartum

    Nature Neuroscience, Vol. 27, Núm. 2, pp. 319-327

2023

  1. Differences in Patterns of Stimulant Use and Their Impact on First-Episode Psychosis Incidence: An Analysis of the EUGEI Study

    Schizophrenia Bulletin, Vol. 49, Núm. 5, pp. 1269-1280

  2. Examining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study

    Psychiatry Research, Vol. 323

  3. Neuroimaging Revealed Long-Lasting Glucose Metabolism Changes to Morphine Withdrawal in Rats Pretreated with the Cannabinoid Agonist CP-55,940 during Periadolescence

    European Neuropsychopharmacology, Vol. 69, pp. 60-76

  4. The relationship between genetic liability, childhood maltreatment, and IQ: findings from the EU-GEI multicentric case–control study

    Social Psychiatry and Psychiatric Epidemiology, Vol. 58, Núm. 10, pp. 1573-1580

  5. Tobacco use in first-episode psychosis, a multinational EU-GEI study

    Psychological Medicine, Vol. 53, Núm. 15, pp. 7265-7276

2022

  1. A replication study of JTC bias, genetic liability for psychosis and delusional ideation

    Psychological Medicine, Vol. 52, Núm. 9, pp. 1777-1783

  2. Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway

    Psychological Medicine, Vol. 52, Núm. 10, pp. 1910-1922

  3. Examining facial emotion recognition as an intermediate phenotype for psychosis: Findings from the EUGEI study

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 113

  4. The association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study

    European Neuropsychopharmacology, Vol. 63, pp. 47-59

2021

  1. Bioactive Synthetic Peptides for Oral Tissues Regeneration

    Frontiers in Materials, Vol. 8

  2. Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings

    Molecular Psychiatry, Vol. 26, Núm. 8, pp. 4529-4543

  3. Examining the association between exposome score for schizophrenia and functioning in schizophrenia, siblings, and healthy controls: Results from the EUGEI study

    European psychiatry : the journal of the Association of European Psychiatrists, Vol. 64, Núm. 1, pp. e25

  4. The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study

    Translational Psychiatry, Vol. 11, Núm. 1

2020

  1. A longitudinal comparison of two neurocognitive test batteries in patients with schizophrenia and healthy volunteers: Time effects on neuropsychological performance and their relation to functional outcome

    Schizophrenia Research, Vol. 216, pp. 347-356

  2. Carboxy-terminal cementum protein 1-derived peptide 4 (Cemp1-p4) promotes mineralization through wnt/β-catenin signaling in human oral mucosa stem cells

    International Journal of Molecular Sciences, Vol. 21, Núm. 4

  3. Cemp1-p3 peptide promotes the transformation of octacalcium phosphate into hydroxyapatite crystals

    Crystals, Vol. 10, Núm. 12, pp. 1-15

  4. Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum

    Epidemiology and Psychiatric Sciences

  5. Nucleation and growth inhibition of biological minerals by cementum attachment protein-derived peptide (CAP-pi)

    Journal of Peptide Science, Vol. 26, Núm. 12

  6. Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene-environment interaction. The EUGEI study

    Psychological Medicine, Vol. 50, Núm. 11, pp. 1884-1897